University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Masters Theses

Dissertations and Theses

July 2016

Sleep Patterns, Urinary Levels of Melatonin and Subsequent
Weight Change in the Women’s Health Initiative Observational
Study
Nicole M. Barron
University of Massachusetts Amherst

Follow this and additional works at: https://scholarworks.umass.edu/masters_theses_2
Part of the Biostatistics Commons, and the Epidemiology Commons

Recommended Citation
Barron, Nicole M., "Sleep Patterns, Urinary Levels of Melatonin and Subsequent Weight Change in the
Women’s Health Initiative Observational Study" (2016). Masters Theses. 395.
https://doi.org/10.7275/8541917 https://scholarworks.umass.edu/masters_theses_2/395

This Open Access Thesis is brought to you for free and open access by the Dissertations and Theses at
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Masters Theses by an authorized
administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.

Sleep Patterns, Urinary Levels of Melatonin and Subsequent Weight Change in
the Women’s Health Initiative Observational Study

A Thesis Presented
by
NICOLE M. BARRON

Submitted to the Graduate School of the
University of Massachusetts Amherst in partial fulfillment
of the requirements for the degree of

MASTER OF SCIENCE

May 2016

School of Public Health and Health Sciences
Department of Biostatistics and Epidemiology

Sleep Patterns, Urinary Levels of Melatonin and Subsequent Weight Change in
the Women’s Health Initiative Observational Study

A Thesis Presented
by
NICOLE M. BARRON

Approved as to style and content by:

________________________________________________
Susan R. Sturgeon, Chair

________________________________________________
Katherine W. Reeves, Member

________________________________________________
Ken Kleinman, Member

________________________________________________
Paula Stamps, Graduate Program Director
Division of Biostatistics and Epidemiology

DEDICATION
To my parents, who taught me the value of hard work, humility, kindness, and perseverance
and for their continued love and support in all that I do.

ACKNOWLEDGMENTS
I would like to thank my advisor, Susan R. Sturgeon, for support and encouragement
throughout this entire process. Your patience and guidance through the challenges and
continued evolution of this project were invaluable. I would also like to thank the members of my
committee for their guidance, comments, and suggestions during this project. Additionally, I
would like to thank Brian Whitcomb, who also had an open door and the time and patience to
teach.
I want to thank the Women’s Health Initiative for the use of their database for this project
and for the comments provided to help improve my project.
A very special and heartfelt thank you goes out to my family and friends, who have
provided endless encouragement and support throughout this process. Things were not always
easy and I am so blessed to have you all in my corner. You held me together when I was
breaking, provided me with a distraction when you knew I needed a break and gave me the
strength to continue to work hard.

iv

ABSTRACT
SLEEP PATTERNS, URINARY LEVELS OF MELATONIN AND SUBSEQUENT WEIGHT
CHANGE IN THE WOMEN’S HEALTH INITIATIVE OBSERVATIONAL STUDY
MAY 2016
NICOLE M. BARRON, B.S., CALIFORNIA UNIVERSITY OF PENNSYLVANIA
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Susan R. Sturgeon

Results from prospective studies examining associations between sleep duration and weight
gain have been mixed. Melatonin has been hypothesized to mediate the association between
sleep duration and weight/body composition. In cross-sectional studies, aMT6s has been shown
to be inversely associated with weight/body fat percentage. We examined associations between
baseline sleep duration, insomnia status, aMT6s levels with weight/body fat percentage through
6 years, utilizing a subset 690 women who participated in a breast cancer case-control study
nested within the WHI-OS. Multivariable and mixed-effects regression was used to calculate
beta-coefficients and 95% confidence intervals. Cross-sectional analyses showed urinary
aMT6s levels were inversely associated with BMI and body fat percentage. No associations
were observed between sleep patterns and measures of adiposity. The prospective relationship
between urinary aMT6 levels and weight/body fat percentage was complex. Age-adjusted
mixed models show an association in the interaction term between year and aMT6s with body
fat percentage (βinteraction:0.09, p<0.01) and a marginally significant association with weight
(βinteraction:0.16, p=0.07), demonstrating the influence of baseline aMT6s and time on changes in
outcome. Women with higher baseline aMT6s had a trajectory of increased body fat percentage
and weight gain steepest between baseline and year 3, whereas women with lower baseline
aMT6 levels had a trajectory of decreased body fat percent and weight between year 3 and year
6. The prospective association between melatonin levels and adiposity measures was
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unexpected. Future studies with objective measures of sleep and repeated measures of
melatonin may shed light of possible explanations for our findings.
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CHAPTER 1
INTRODUCTION
In the past four decades, the prevalence of obesity (body mass index (BMI) ≥30kg/m2) in
the United States has nearly tripled, from 13% in 1960s to 36% in 2011-2014(1, 2). In 20112014, the prevalence of obesity in U.S women aged 60 and older was 38.8% according to the
National Center for Health Statistics (2). Obesity is associated with increased risk for
cardiovascular disease, cancer, diabetes, and decreases in quality of life (3). Body fat
distribution may be even more strongly related to embolic disturbances and cardiovascular
morbidity and mortality than BMI (4).
Temporal increases in the prevalence of insufficient sleep are also hypothesized to have
contributed to the obesity epidemic (5). Laboratory and animal studies have shown that blood
leptin levels have specific patterns of secretion, with peaks during sleep. Shortened sleep
results in decreased leptin circulation and increased ghrelin, which is associated with increased
appetite and caloric intake (6). Based on the National Health Interview Survey, nearly 30% of
adults reported less than the optimal sleep of 7-8 hours per day in 2005-2007 (7). Increases in
sleep insufficiency may reflect modern society with its long working hours, shiftwork, widespread
use of artificial lighting and technology use around the clock (8).
Results from prospective studies of adults that have examined the association between
sleep duration and weight gain have been mixed. Many have found shorter sleep durations to
be associated with weight gain over time (9-15), while others have not (16-19). Results from the
most recent studies that considered a women’s menopausal status and performed a separate or
stratified analysis in pre- and post-menopausal women are presented in Table 1. A study
investigating sleep duration, weight change, and obesity was conducted among 2,269 women in
Spain aged 60 years and above (12). Sleep duration was self-reported and weight was
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measured during a home-based personal interview. Over a 2 year follow-up period, they found
women who reported 5 hours or less of sleep of sleep were more likely to gain weight
≥5kg,than average (7 hours) sleepers (OR:3.41 95%CI:1.34,8.69) (12). They also observed an
increased frequency of gaining ≥5kg among women sleep for 8 and 9 hours nightly than
average sleepers (OR:3.03 95%CI:1.29,7.12) and (OR:3.77 95%CI:1.55,9.17), respectively.
This study was unique in that it adjusted for depression status, chronic diseases, light at night,
and intentional weight loss in analysis (12). Overall, evidence also suggests a link between
greater than eight hours of sleep and weight gain. In agreement with Lopez-Garcia, et al (2008),
there was a U-shaped relationship between sleep duration and weight in cross-sectional
analyses in a Nurses’ Health Study that examined short sleep with weight gain in 68,183 women
where those sleeping for ≥9 hours had a higher baseline weight (68.2kg), as compared to
women sleeping for 7 hours (67.0kg) (10, 12).
Research suggests that sleep duration is also associated with body composition. In a
recent meta-analysis of 21 cross-sectional studies published from 2007-2013, sleep duration
was negatively correlated (r:-0.10) with waist circumference, a marker of abdominal obesity
(20). Some longitudinal evidence suggests that short sleep may be associated with greater
abdominal obesity or visceral fat gain than average duration (7 hours) of sleep longitudinally,
even after adjustment for body weight (11, 21, 22). Adult participants in the Quebec Families
Study (men and women aged 18-65 years) were assessed at baseline and again at year 6 for
sleep duration and visceral adipose tissue. Study results revealed that those participants who
reported sleep duration ≤6hours or ≥9hours as compared to those reporting 7-8 hours at
baseline gained significantly more visceral fat over 6 years (23.4cm2, 20.2cm2, and 14.1cm2,
respectively) (21).
There has been limited research on the possible association between insomnia and
measures of body weight and composition. The results of studies have been mixed with some
2

clinical studies suggesting no evidence of increased body weight in individuals with insomnia
whereas a few studies have suggested increases in appetite hormones and weight gain
associated with insomnia in a mixed-sex population (23-25). A study conducted among male
and female clinically diagnosed insomnia participants with a mean age of 42.2 years observed a
negative correlation between poor sleep quality and BMI (r:-0.023) (24).
Melatonin is a circulating hormone known to rhythmically regulate the sleep-wake cycle
over 24 hours, with its highest concentration typically seen between 2-3am (26). Circadian
rhythm disruption has been extensively examined and found to be associated with numerous
factors including sleep duration, insomnia, and melatonin (27). Lower melatonin levels have
been associated with shorter sleep duration in mixed-gender populations (28), and melatonin
has been hypothesized to mediate the effect of sleep duration on body weight (29-31). While
melatonin is more commonly thought to influence sleep and mood, it was thought that it may in
turn influence insomnia. Insomnia is difficult to define as it is largely based on subjective
complaints (32). The DSM-IV and ICD-10 code defines diagnosis of insomnia based on
responses to the Pittsburgh Sleep Quality Index (33) and Insomnia Severity Index (34) listing
complaints of difficulty initiating, maintaining, and non-restorative sleep. However, to date, there
has been no compelling evidence that symptoms of insomnia are related to melatonin levels
(35). Until this point, there have been no prospective studies to evaluate not only sleep duration
and insomnia, but also baseline urinary levels of melatonin metabolite as a predictor of weight
gain or fat mass in post-menopausal women. However, six cross-sectional studies have
examined urinary melatonin levels and BMI or weight (36-41).
The only cross-sectional study that examined urinary melatonin levels as a predictor of
change in weight was by Ramin and colleagues in the Nurses’ Health Study II cohort (41). They
examined information obtained from 1,343 woman aged 32 to 53 years to investigate the
association of early to mid-life body size with urinary aMT6s levels among night shift workers.
3

Women who gained more than 20kg since age 18 had lower concentrations of urinary aMT6s
(36ng/mg) compared to women who reported gaining 5kg-20kg (42ng/mg) and women reporting
gaining less than 5kg (45ng/mg), respectively. Adjustments in this analysis were made for age
at urine collection, first-morning urine, batch, number of pack-years smoked, parity, physical
activity in MET-hours per week, and night shift work in 2 weeks prior to urine collection (41).
Neither sleep duration nor insomnia were considered in the analysis.
To investigate the associations between baseline sleep duration, baseline insomnia
status, baseline melatonin levels and weight changes/body fat percentage changes over time
we analyzed a subset of women who participated in a breast cancer case-control study nested
within the Bone Density Substudy in the WHI OS. We hypothesized that through 6 years of
follow-up, women who slept for less than or more than 7 hours a night at baseline would have
greater increases in weight and body fat percentage than women who slept for 7 hours a night,
that women classified as having insomnia at baseline would have greater increases in weight
and body fat percentage than women who were not classified as having insomnia, and that
women with lower levels of mean aMT6s at baseline would have greater increases in weight
and body fat percentage than women with higher levels of mean aMT6s at baseline.
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CHAPTER 2
METHODS
Study Population
The WHI-OS consists of 93,676 postmenopausal women who were 50-79 years of age at the
time of their enrollment. They were recruited through the use of community-based methods at
40 U.S. clinical centers from 1994 to 1998 (37). Women were excluded from participation if they
had a condition that would encumber study compliance (issues with substance abuse or
dementia, etc.), a condition with a less than 3 year predicted survival, or did not plan to reside in
the area for at least 3 years (42). A baseline screening conducted by a medical professional and
an extensive questionnaire was completed by each woman after study enrollment and annual
questionnaires were sent out via mail to collect updated information on selected exposures and
medical outcomes (37). The bone density sub-study of the WHI-OS was conducted in three
clinical sites (Pittsburgh, Birmingham, and Tucson). DXA measurements were collected at
baseline, year 3, and year 6 clinic visits on this subpopulation of approximately 10,000 women.
Data from a previous nested case-control study on urinary levels of melatonin and breast
cancer were used in this analysis. Study procedures have been described in detail elsewhere
(37). Briefly, the study population of the nested case-control study was identified using women
who were participants in a bone density sub-study of the WHI-OS enrolled at three clinical
centers and also provided a urine specimen at baseline. The initial study population was
comprised of 852 women, of whom 284 were breast cancer cases and 568 were controls (37).
Women who had creatinine-standardized aMT6s concentrations and sleep pattern measures
available at baseline and BMI (n=690) and percentage body fat (n=684) measures reported at
baseline were included in our primary analysis.
Sleep Duration Assessment
Sleep duration was assessed at baseline using the question “About how many hours of sleep
did you get on a typical night during the past 4 weeks?” (42, 43). There were six categories of
5

responses coded from 0 (most hours slept) to 5 (least hours slept). The response options
included 10 or more, 9, 8, 7, 6, 5 or less hours (43). These response categories were collapsed
to “6 hours or less”, “7 hours”, and “8 hours or more” for data analysis.
Insomnia Assessment
Insomnia was assessed at baseline using the Women’s Health Initiative Insomnia Rating Scale
(43). The questions were designed to assess sleep habits and insomnia, with each being scored
between 0 and 4, for an overall possible score of 20. A score of 9 or above is considered
evidence for insomnia. The first four questions assessed the frequency of occurrence over the
last four weeks. The questions, “Did you have trouble falling asleep,” “Did you wake up several
times at night,” “Did you wake up earlier than you planned to,” and “Did you have trouble getting
back to sleep after you woke up too early,” had five potential responses which included no, less
than one weekly occurrence, 1-2 weekly occurrences, 3-4 weekly occurrences, 5 or more
weekly occurrences, that corresponded to participants’ sleep experiences.. The fifth question
assessed the quality of sleep over the past four weeks, with response options of “very sound or
restful,” “sound or restful,” “average quality,” “restless,” and “very restless” (37). This 5-question
rating scale has been validated through its use in several studies and comparing the results to
the results the findings of validated sleep quality and insomnia rating scales (43).
Melatonin Assessment
With a half-life of 35 to 50 minutes, serum melatonin undergoes rapid metabolism in the liver
resulting in the primary urinary metabolite, 6-sulphatoxymelatonin (aMT6s) (26). Due to this
metabolism, aMT6s is usually measured via a single morning urine sample or samples collected
over a 24 hour period. Both methods adjust samples for creatinine to account for differences in
urine concentration. WHI collected first morning voids. Urinary 6-sulfatoxymelatonin (aMT6s)
was assessed through a competitive ELISA (Buhlmann Laboratories AG) and were adjusted for
creatinine levels to control for urine concentration (37). Concentration of urinary creatinine was
determined through colorimetric analysis in ng/mg. In total, 40 masked duplicates were included
6

across three batches. The intra-assay coefficient of variation for unadjusted melatonin levels
were 12.5% and 12.7% and the intra-assay coefficient of variation for unadjusted creatinine
levels were 9.1% and 5.8% (37).
Weight Assessment
Weight was measured in kilograms and height was measured in meters by trained personnel at
the WHI clinic visits at or near enrollment, at year 3 and year 6 using a calibrated balance beam
scale (42). These variables were analyzed continuously. Body Mass Index for each collection
time was calculated from weight and height measures. This variable was categorized as “normal
weight” (<25kg/m2), “overweight” (25 to <30kg/m2), and “obese” ≥30kg/m2).
Percentage Body Fat Composition Assessment
A dual energy X-Ray absorptiometry (DXA) scan was used to measure body composition at
baseline and at years 3 and 6 of follow-up (42). The body composition assessments provide
data on the components that make up a person’s weight that is more informative then BMI
measures alone in that the DXA scan noninvasively assesses percentage body fat. This
assessment provides individualized information on the distribution and composition of fat (21).
The WHI corrected form of this variable was utilized, as it flagged and accounted for movement
or other obstructed appearance in initial scan and reported a repeated the measure if necessary
(44). This variable was measured continuously. All women had their DXA scans completed on
comparable versions of the Hologic QDR-2000 bone denisitometer scanner at each time point
(44).
Covariate Assessment
Information was available at baseline on the following factors: age, ethnicity (White,
Black/African American, Other), education (<high school, high school to <college, college to
<post-graduate study, ≥post-graduate study or degree), family income (<$35,000, $35,000$75,000, ≥$75,000, unknown), employment status (not employed, employed), marital status
(never married, widowed/divorced/separated, married/marriage-like relationship), personal
7

history of diabetes, personal history of stroke, alcohol consumption (non-drinker, former drinker,
<1 drink/month, <1 drink/week, 1-<7 drinks/week, ≥7 drinks/week), energy expenditure from
physical activity (METS hr/week), cigarette smoking (never, past, current), caffeine consumption
(mg), daily caloric intake (tertiles, kcal/day), modified healthy eating index (tertiles, 0-100 scale,
closer to 100 indicates better adherence to dietary recommendations), depression status (0-1
scale, ≥0.6 signifies depression), social strain (4-20 scale, closer to 20 signifies more social
strain), physical functioning (0-100 scale, closer to 100 signifies more favorable physical
function) and emotional limitations (0-100 scale, closer to 100 signifies more favorable
emotional state). Information for each covariate was obtained at baseline from its corresponding
questionnaire. All variables above were selected for inclusion based on their known relationship
with melatonin and/or sleep patterns and weight and/or body composition or due to prior their
inclusion in literature evaluating similar exposure and outcome associations (10, 15, 36-41, 45,
46).
Statistical Analysis
Initial summary statistics and frequency distributions were conducted for all variables at
baseline. Chi-square or Analysis of variance (ANOVA) were performed as appropriate to
examine the distribution of BMI, weight, body fat percentage, and covariates by sleep duration,
insomnia or aMT6s . Due to skewed urinary melatonin metabolite data, creatinine-adjusted
aMT6s values were log-transformed and geometric means reported.
Overview
We conducted three main analyses for each of the three exposures (sleep duration, insomnia,
and aMT6s) with the two outcomes (BMI/weight and body fat percentage). Initially we assessed
the association between the exposures at baseline and the outcomes at baseline. We followed
the baseline analysis by assessing the association of baseline exposures with outcomes at year
6, adjusting for baseline outcome and covariates. Finally, we utilized linear mixed-effects
models that incorporate the repeated measures of weight and body fat percent, from baseline,
8

year 3 and year 6, to assess their changes associated with sleep duration, insomnia, and
aMT6s through the 6 years of follow-up.
Baseline
Linear regression was used to assess the relationship of sleep duration categories, insomnia
score, and adjusted urinary melatonin metabolite concentrations on weight and percentage
body fat at baseline. Multivariable linear regression models were used to assess the relationship
between the exposures and outcomes after adjustment for potential confounders as determined
from bivariate analysis (p<0.1) and biological importance from prior literature (15, 45). Due to
the large number of potential confounders, models were created and run with subsets of related
potential confounders were grouped to assess the change in effect of that model subset. If the
change in effect of a particular model was greater than 10%, then the confounders in that model
were further investigated. Confounders including age (Model 1), sleep duration, insomnia,
aMT6s (Model 2, as appropriate), education, ethnicity, marital status (Model 3), HEI score, daily
caloric intake, weekly energy expenditure (Model 4), depressive symptoms, physical functioning
and emotional limitations constructs (Model 5), smoking, alcohol intake (Model 6), personal
history of diabetes or stroke (Model 7), with all models after Model 1 being adjusted for age. A
final was fit including covariates from all models. To assess potential mediation, an additional
model was fit excluding sleep duration, insomnia, or aMT6s, as appropriate. Only subjects with
information available on all exposure, outcome, and covariates were included in the models and
analysis was repeated for all exposures and body composition variables. Beta coefficients with
95% confidence intervals and p-values were presented.
Year Six
As with linear regression analyses conducted on the baseline outcomes, the relationship
between sleep duration categories, insomnia score, and adjusted urinary melatonin metabolite
concentrations on weight and percentage body fat at year 6 was completed in the same
manner. Analysis for outcome measures at year 6 were conducted using the same modeling
9

process and groupings, with the addition of an age and baseline weight/body fat percentage
adjusted model and all subsequent models being adjusted for both age and baseline
weight/body fat percentage. Only subjects with information available on all exposure, outcome,
and covariates were included in the models. Analysis was repeated for all exposures and body
composition variables. Beta coefficients with 95% confidence intervals and p-values were
presented.
Mixed Models
The relationship between sleep duration, insomnia status, and aMT6s levels with repeated
measures of weight and body fat percentage was assessed using linear mixed-effects
regression models. Intercepts and slope were random and an interaction term between year
and sleep duration, insomnia status, or aMT6s levels, as appropriate, was added to each model
to assess the influence of the exposure on change in body fat percentage or weight. The same
series of models used in the year 6 linear regression analysis was also utilized for the linear
mixed models. This secondary analysis was limited to 490 study participants who had complete
data available for baseline measures of sleep duration, insomnia status, aMT6s, and pertinent
covariates, as well as, weight and body fat percentage at all three time points (0,3,6).
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CHAPTER 3
RESULTS
A total of 690 women who participated in the original breast cancer nested-case control
study had sleep duration, insomnia, and aMT6s data available, as well as complete data on BMI
and covariates and 684 had data available for all three exposures, body fat percentage and
covariates. The average age of study participants was 63 years at baseline. As shown in Table
2, nearly 62% were overweight or obese and the average percentage body fat was 43%.
Approximately 33%, 41%, 25% of the population reported sleeping for 6 or less hours, 7 hours,
and 8 or more hours, respectively. Nearly 30% of the participants met the criteria for insomnia
and the mean creatinine-adjusted aMT6s level was 16.1ng/mg. Overall, the majority of women
where white, married, and had had some college level education. Few women were current
smokers and the majority reported current consumption of alcohol.
In total, 56% of participants were not currently employed and nearly half reported
earning less than $35,000 annually. Few women had a prior diagnosis of diabetes, stroke, or
myocardial infarction. The mean total daily caloric intake was 1539.6±662.8kcal/day and the
average modified healthy eating index score of 68.6±10.5, where a score closer to 100 indicates
better adherence to dietary guidelines. Overall, 20% of the population had a mean energy
expenditure from moderate physical activity falling within the recommended range of 8.3 to 16.7
METS hr/wk (47) as opposed to 51% falling below this recommendation. The majority of the
women did not exhibit depressive symptoms (88.1%) and had mean physical functioning and
emotional limitations construct scores of 80.6 and 84.5 respectively, where scores closer to 100
indicate a more favorable health state.
Sleep Duration
The distribution of baseline sociodemographic and lifestyle characteristics by sleep
duration category are presented in Table 3. Women in this category tended to be 60-69 years of
age, fell into the “normal weight” category for BMI, had a higher mean aMT6s as compared to
11

other sleep duration categories, and did not report insomnia or depressive symptoms. They had
similar body fat percentages and higher scores for both the physical functioning and emotional
limitations constructs as compared to other sleep duration categories. The majority of women
falling into the lowest tertile of HEI score slept for 6 hours or less nightly and those women
falling into the higher tertiles slept for 7 hours nightly.
Results for all multivariable linear regression models of sleep duration for body mass
index and body fat percentage at baseline are presented in Tables 4 and 5. We did not observe
a statistically significant association between sleep duration (7 hours as reference) with 6 hours
of sleep or less (β -0.06, 95%CI:-0.08-0.20) or 8 hours of sleep of more (β 0.06, 95%CI:-0.090.20) with body mass index in the age-adjusted model. We also did not observe a statistically
significant association for sleep duration (7 hours as reference) with 6 hours of sleep or less (β 0.05, 95%CI:-0.18-0.09) or 8 hours of sleep of more (β 0.02, 95%CI:-0.12-0.16) with body mass
index in the fully-adjusted model. In the age-adjusted and fully-adjusted models for sleep
duration and body fat percentage, we did not observe an association of sleep duration (7 hours
as reference) in 6 hours of sleep or less (β -0.45, 95%CI:-1.73-0.84) or 8 hours of sleep or more
(β 0.21, 95%CI:-1.19-1.60) [age-adjusted] and 6 hours of sleep or less (β -1.09, 95%CI:-2.320.13) or 8 hours of sleep of more (β 0.13, 95%CI:-1.15-1.40) [fully-adjusted] with body fat
percentage. In tables 6 and 7, we examined sleep duration and weight and body fat percentage
at year 6 and observed no association (p>0.05).
Insomnia
In Table 8, we observe that overall most women did not have insomnia (n=530). The
majority of women classified as having insomnia fell into the sleep duration category of 6 hours
or less. Women classified as having insomnia had lower scores for both the physical functioning
and emotional limitations constructs as compared to women with no insomnia classification (75
& 73 vs. 83 & 90). The prevalence of depressive symptoms also varied by insomnia status.
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Results for multivariable linear regression models of insomnia status for body mass
index and body fat percentage (baseline) are presented in Table 9. In both our age-adjusted
and fully-adjusted multivariable models of insomnia status, with no insomnia serving as our
reference group, we observed no statistically significant association of insomnia (β 0.04,
95%CI:-0.09-0.17) and (β -0.02, 95%CI:-0.15-0.11) with body mass index. We also did not
observe an association in our age-adjusted or fully-adjusted models for insomnia (β 0.45,
95%CI:-0.75-1.65) and (β 0.32, 95%CI:-0.88-1.52) with body fat percentage.
We also explored the association between insomnia status and weight and body fat
percentage at year 6. The results of these analyses are presented in Table 10. No association
was observed between insomnia status and weight at year 6, or insomnia status and body fat
percentage at year 6 in our age-adjusted or fully-adjusted models.
Melatonin
Analysis of urinary aMT6s with covariates yielded some variations in mean aMT6s within
covariate categories (Table 11). Overall, we observed a decrease in mean aMT6s as age and
BMI categories increase. White women had higher mean aMT6s than black women and women
of other ethnicities, 11.9ng/mg, 8.3ng/mg, and 9.9ng/mg respectively and women who were
married had higher mean aMT6s than women in other categories. Women with diagnosis of
diabetes had a substantially lower mean aMT6s compared to women with no diagnosis of
diabetes, 6.8ng/mg and 11.6ng/mg. Women who were current drinkers had increased mean
aMT6s than non- and former drinkers (~12.3ng/mg vs 10.5ng/mg and 9.4ng/mg). Mean aMT6s
was significantly correlated with percentage body fat and the physical functioning construct (0.164 and 0.124). Overall, 32% of women lost more or less than 2.3kg (equivalent to 5lbs) over
the 6 years of follow-up. The women making up these groups also had urinary aMT6s levels of
13.4 and 14.9ng/mg, respectively, as compared to 21.1ng/mg for women with no change in
weight.
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Results for multivariable linear regression models of log-transformed aMT6s for body
mass index and body fat percentage (baseline) are presented in Table 12. In the age-adjusted
model we observed that there was no deviation from the unadjusted model. In our fully-adjusted
multivariable model for body mass index, we observed a significant inverse association between
aMT6s and BMI. For each 1 unit increase in log aMT6s (ng/mg of creatinine), BMI decreased by
0.09 kg/m2, holding all other variables constant. The results of this model can be translated to a
10 unit increase in aMT6s results in a decrease in BMI of 0.1 kg/m2, holding all other variables
constant when considering the non-log transformed adjusted urinary melatonin variable. In our
fully-adjusted multivariable model for body fat percentage, we also observed a significant
inverse association between aMT6s and body fat percentage. For each 1 unit increase in log
aMT6s (ng/mg of creatinine), body fat percentage decreased by 0.63%, holding all other
variables constant. These results translate to a 10ng/mg increase in aMT6s results in a
decrease in body fat percentage of 0.5%, holding all other variables constant in the fullyadjusted model using the non-log transformed adjusted urinary melatonin. There was no strong
evidence of potential confounding in either model.
We also explored the association between aMT6s and body weight and body fat
percentage at year 6. The results of mean aMT6s for body weight and body fat percentage
(year 6) are presented in Table 13. In the age-adjusted model for body weight, we found a
significant inverse association between log-transformed aMT6s and body weight (β:-1.77
95%CI:-3.35,-0.19). This association was no longer present upon adjustment for baseline body
weight in subsequent models. No association was observed between aMT6s and body fat
percentage at year 6 in our age-adjusted or fully-adjusted models.
Mixed Models
Sleep duration at baseline was not found to be associated with body fat percentage or its
interaction with follow-up time in any of the models (data not shown), including the full model (β:
-0.06 (0.04), p=0.13). Sleep duration at baseline was not found to be associated with weight or
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its interaction with follow-up time in any of the models, including the full model (β:-0.09 (0.10),
p=0.37). Insomnia status at baseline was not found to be associated with body fat percentage or
its interaction with follow-up time in any of the models, including the full model (β: 0.08 (0.07),
p=0.21). Insomnia status at baseline was also not found to be associated weight or its
interaction with follow-up time in any of the models, including the full model (β: 0.04 (0.18),
p=0.82).
Mixed models analyzing weight and body fat percentage according to baseline logadjusted aMT6s are presented in Figures 1 & 2. Log-adjusted aMT6s at baseline was
significantly associated with body fat percentage change over time, as was its interaction with
follow-up time (p<0.01). The interaction term remained significantly associated with body fat
percentage after all model adjustments and in the full model. Therefore, for each 1 unit increase
in log aMT6s (ng/mg of creatinine), body fat percentage increased by 0.09% per year. Logadjusted aMT6s at baseline was found to be significant with weight (p<0.05) and its interaction
with follow up time was marginally significant (p=0.07). The interaction term remained
marginally significant throughout all model adjustments and in the full model. Therefore, for
each 1 unit increase in log aMT6s (ng/mg of creatinine), body weight increased by 0.16kg per
year.
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CHAPTER 4
DISCUSSION
In our study, we found no association in either cross-sectional or prospective analyses
between sleep duration and BMI/body weight or body fat percentage. We also found no
evidence in either cross-sectional or prospective analyses between insomnia and BMI/body
weight or body fat percentage. Cross-sectionally, we observed a statistically significant inverse
association between urinary levels of melatonin metabolite (aMT6s) and measures of body
mass index and composition where increased baseline levels of aMT6s were associated with a
slightly higher BMI and slightly higher body fat percentage. We found no evidence of an
association between baseline aMT6s levels and body weight at year 6. However, we observed a
borderline statistically significant positive association between aMT6s and body fat percentage
at year 6 where higher levels of baseline aMT6s were associated with increased body fat
percentage at year 6.
Although some prospective studies observed statistically significant associations
between ≤6 hours sleep duration with an increase in weight (9-15), other studies have been null
(16-19). In general, studies that have examined the relationship between short sleep duration
and weight gain have been stronger in adolescents and children (48), while the association
between sleep duration and weight gain has not been consistently suggested in older adults
(10, 12, 16) and may diminish with age . Furthermore, studies have suggested that the
association with weight gain may be stronger in individuals who weigh less (49, 50). At entry,
the mean age of the women in our study at entry was 63.5 years and over 60% of the women in
our study were overweight or obese. The follow-up time of our study was also relatively short
which may have made it more difficult to find an association. When comparing it to studies of
older individuals, the women in a study conducted by Lopez-Garcia, et al (2008) who had a
mean age of 72.1 years and over 78% who were considered obese, with 7.5 years of follow-up
(12) and Xiao, et al (2013) who were 51-72 years old and 20% who were considered obese,
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with 2 years of follow-up (15), found associations with short sleep duration (≤5 hours) in which
the longer follow-up time and younger study population, respectively, could have influenced our
inability to find an association(12, 15). Long sleep durations and weight gain have been more
inconsistent (6, 10, 11).
Few studies have looked at the association between sleep duration and body fat
percentage. Results from a prior cohort study of 276 male and female participants, aged 21 to
64 years, that focused on sleep duration and body composition changes over 6 years,
suggested that shorter (5-6 hours) and longer (9-10hours) sleep duration is associated with an
increased body fat percent as compared to those sleeping 7-8 hours (11).
Similar to our findings for insomnia, two prior studies observed null results (24, 25)
whereas Crönlein et al. (2015) observed a significantly lower weight among women with
insomnia in a cross-sectional study conducted in a well-defined large clinical sample
predominantly of older women (82% women vs. 18% men).
We observed a cross-sectional association between urinary levels of melatonin
metabolite (aMT6s) and body mass index, where increased baseline levels of aMT6s were
associated with a slightly lower BMI. In agreement with our results, other cross-sectional studies
have found a significant inverse association between urinary melatonin metabolite and BMI (3641, 51, 52). A study conducted among 1,343 female night-shift workers selected from the
Nurses’ Health Study II aged 32-53 years found women in the lowest quartile of aMT6s had
higher BMI than women in the highest quartile of aMT6s (41). This same study also investigated
the association of early to mid-life body size with urinary aMT6s levels and found no association
between current aMT6s levels and average somatotype in childhood, however an inverse
association between baseline aMT6s and waist circumference was observed. Moreover, studies
have suggested that adult BMI may influence melatonin’s’ mediation of circadian rhythms more
so than body size earlier in life (41). One potential biological mechanism proposed to link
melatonin with weight and BMI is related to the presence of melatonin in the liver. Melatonin
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may be involved in the accumulation of fatty acid-induced triglycerides in the liver, preventing an
increase in the levels of circulating triglycerides (53, 54). Increases in the levels of circulating
triglycerides has been linked to increased food intake and subsequent weight gain (53).
While we observed the presence of a significant cross-sectional association between
aMT6s and BMI and body fat percentage, we failed to observe an association in prospective
analyses. This may be due our relatively short period of follow-up, which may have hindered our
ability to observe the long-term influence of melatonin on weight and body fat percentage.
Another possible explanation is the age-related decrease of melatonin levels of women in this
study population may have less of an impact on weight and body fat percentage, as compared
to younger women.
Women with higher baseline melatonin levels had an unexpected trajectory of increased
body fat percentage and weight gain which was steepest between baseline and year 3, women
with intermediate baseline melatonin levels had relatively stable body fat percentage and weight
over time, and women with lower baseline melatonin levels had a trajectory of body fat
percentage and weight loss, which was steepest between year 3 and year 6. Dissimilar to the
inverse association observed in our cross-sectional analyses, as well as, prior literature, mixed
models analysis revealed higher levels of aMT6s at baseline were not suggestive of a clear
overall decrease body fat percentage and weight during follow-up. Our study had only single
baseline measure of urinary melatonin levels and thus it is difficult to know if changes in
melatonin over time accounted for the complex patterns observed over time. Overall,
differences were small and results may have occurred by chance.
To our knowledge, this is the first prospective study of post-menopausal women to
examine the association of baseline urinary melatonin metabolite, sleep duration and insomnia
status with body fat percent and weight over time. The prospective nature of the study
strengthens our analyses, as does the in-clinic measures of weight, height, and body fat
percent, the validated sleep and insomnia questionnaires, the collection and analysis of urine for
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aMT6s levels prior to evaluation of weight and body fat percentage, and the extensive data that
was collected on potential confounding variables.
This study is limited by the self-report nature of sleep duration and no clinical diagnosis
of insomnia, but rather self-report responses to a series of questions that are scored to assign
insomnia status. The self-reported nature of both the sleep duration and insomnia variables is
subjective and the measure was only taken once and was based upon sleep duration and
insomnia habits in the past 4 weeks only, therefore non-differential misclassification of exposure
could have influenced our null findings through underestimation of effect estimates. A study by
Kripke, et al, conducted on 350 women within the WHI-OS, observed a relatively weak
correlation (r: 0.37) between responses to the WHI questionnaire and results of 7-nights of wrist
actigraphy, which further suggests that our results may be underestimates resulting from nondifferential misclassification of exposure (55).
Sleep duration responses from self-report questionnaires were collapsed from the six
original WHI categories into 3 sleep duration categories for meaningful analysis in this study
population. This category collapse eliminated our ability to examine associations in shorter (≤5
hours) or longer (≥9 hours) sleep duration categories with sleep duration similar to those
observed in previous literature (10, 12, 15, 22). Misclassification of this nature is likely to have
biased our results toward the null.
Urinary melatonin metabolite was ascertained through the first morning midstream spot
void at baseline. This method is subject to misclassification if a woman if a women had an
overnight void prior to the first morning void or if a sample collected at a later time that was
mislabeled as the first morning void resulting in aMT6s measures that are an underestimate of
the overnight peak. Additionally, the single measure of aMT6s may be subject to intra-person
variation, therefore some women may have their aMT6s level misclassified. If this nondifferential misclassification occurred, our results would be underestimated and the bias would
be toward the null. As WHI protocol instructed women as to the importance of first morning void
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collection and due to first morning aMT6s concentrations remaining fairly stable with repeated
measures over several years (ICC:0.72, 95%CI: 0.65, 0.82), misclassification of this type is of
minimal concern (42, 56).
The parent nested-case control study considered the risk of aMT6s on breast cancer
(37). We acknowledge that a large proportion of our study population developed breast cancer
during follow-up, and this breast cancer diagnosis may influence our exposure and/or outcome
measures. To evaluate the potential impact of breast cancer status, we conducted separate
analyses in controls which showed results similar to the overall study population. We are further
reassured by results of our analyses in the overall study population behaving similarly to prior
literature.
In summary, the link between self-reported sleep duration and subsequent weight gain
and, to a lesser extent, body composition has been studied in a number of studies with mixed
results. Future studies should focus on the relationship between objective sleep measurements
and weight and body composition. Further work is also needed to understand the inverse
association between urinary levels of melatonin and obesity which has been observed in a
number of cross-sectional studies.
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Table 1. Most recent sleep duration and weight studies that consider menopause status in women
Author,
year
Applehans,
2013

Study
Population
SWAN Sleep
Study, 310 postmenopausal
women
Avg follow-up:
3yrs

Exposure &
Assessment
Sleep; 3 selfreport by
actigraphy &
sleep diary
assessment

Outcome &
Assessment
BMI calculated
from Height &
Weight;
measured on
calibrated scale

Xiao, 2013

NIH-AARP Diet &
Health Cohort
Study, 40,201
Women aged 5172 years
Spanish
Populationbased, 2,269
women baseline
≥60 years

Sleep duration;
self-reported 2
time points

Weight change,
self-report

Nurses’ Health
Study; 68,183
women aged 3965 years

Sleep duration,
self-reported in
the 1986
questionnaire
(baseline)

LopezGarcia,
2008

Patel, 2006

Sleep duration,
home-based
personal
interview

Effect Estimate
0.06 (95%CI: -2.28, 2.40), n=33

Weight gain
<5hrs: 0.43kg (95%CI: 0.00, 0.86)
5-6hrs: 0.23kg (95%CI: 0.08, 0.37)
≥9: no association
as compared to 7-8 hours
Weight gain, self- Weight gain >0.1kg≤5hrs (OR:3.41
report
95%CI:1.34, 8.69)
6 hours: no association
8hrs: (OR:3.03 95%CI:1.29, 7.12)
9hrs: (OR:3.77 95%CI 1.55, 9.17)
<9hours : no association
as compared to 7 hours
Weight gain, self- Weight
reported
≤5 hour: 2.47kg (95%CI:1.97, 2.98);
biennially
6hrs: 1.24kg (95%CI:0.99, 1.29) as
>7hrs of sleep: no association
compared to 7 hours, no association
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Table 2. Baseline characteristics of study population in the Women’s Health
Initiative, N=690
Characteristics

Participants
n (%)
Mean ± SD

Urinary Melatonin Metabolite
aMT6s (ng/mg of creatinine)

16.5±12.6

Sleep Duration
6 hours or less

229 (33.2)

7 hours

285 (41.3)

8 hours or more

176 (25.5)

Insomnia Rating

6.6±4.4

No (<9)

481 (69.7)

Yes (≥9)

209 (30.3)

Age in years

63.2±7.1

Body Mass Index (kg/m2)

27.9±6.1

Normal Weight (<25 kg/m2)

259 (37.5)

Overweight (25 to <30 kg/m2)

239 (34.6)

Obese (≥30 kg/m2)

192 (27.8)

Body Fat Percentage

42.9±7.3

Missing (N)

16

Fat Mass (kg)

31.6±11.4

Missing (N)

16

Lean Mass (kg)

38.0±5.2

Missing (N)

16

Weight (kg)

73.1±16.4

Height (m)

1.6±0.1

Education
Less than High School

46 (6.7)

High School to <College

229 (33.2)

College to <Post-graduate Study

239 (34.6)

≥Post-graduate Study or Degree

179 (25.5)
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Ethnicity
White (Non-Hispanic)

630 (81.1)

Black or African-American (Non-Hispanic)

93 (12.0)

Other

54 (6.9)

Income Status
<$35,000

323 (46.8)

$35,000 - $75,0000

227 (32.9)

≥ $75,000

90 (13.0)

Missing (N)

50

Employment Status
Not employed

387 (56.1)

Employed

185 (26.8)

Missing (N)

118

Marital Status
Never Married

26 (3.8)

Widowed/Divorced/Separated

212 (30.7)

Married/Marriage-like relationship

452 (65.5)

Total Caloric Intake (kcal/day)
Tertile 1 (240.8-1250.4)

923.2±230.9

Tertile 2 (1251.1-1719.7)

1473.2±136.5

Tertile 3 (1721.6-6546.0)

2205.0±561.0

Modified Healthy Eating Index
Tertile 1 (36.4-65.87)

56.5±6.8

Tertile 2 (65.88-74.74)

70.4±2.5

Tertile 3 (74.78-89.7)

79.3±3.2

Prior Diagnosis of Diabetes
No

650 (94.2)

Yes

40 (5.8)

History of Stroke
No

686 (99.4)

Yes

4 (0.6)
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History of MI
No

672 (97.4)

Yes

18 (2.6)

Cigarette smoking
Never

365 (52.9)

Former

277 (40.1)

Current

48 (7.0)

Alcohol consumption
Non drinker

109 (15.8)

Former drinker

141 (20.4)

Current drinkers
<1 drink per month

92 (13.3)

<1 drink per week

131 (19.0)

1 to <7 drinks per week

151 (21.9)

7+ drinks per week

66 (9.6)

Caffeine Consumption (mg)

169.4±135.3

Energy expenditure from physical activity (METSa hr/wk)

12.5±14.0

Social Strain

6.4±2.5

Missing (N)

6

Physical Functioning

81.0±19.5

Depressive Symptoms

0.04±0.13

No (<0.06)

610 (88.4)

Yes (≥0.06)

80 (11.6)

Limitations due to emotional problems
a METS

84.1±30.3

(metabolic equivalent task scores)
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Table 3. Sleep duration by study population characteristics in the Women’s Health Initiative, N=690
Characteristic

6 hours or less
N=229
N (%) /Mean±SD

7 hours
N=285
N (%) /Mean±SD

8 hours or more
N=176
N (%) /Mean±SD

76 (33.2)

88 (30.9)

57 (32.4)

107 (46.7)

138 (48.4)

88 (50.0)

46 (20.1)

59 (20.1)

31 (17.6)

Normal Weight (<25 kg/m2)

83 (36.3)

111 (38.9)

65 (36.9)

Overweight (25 to <30 kg/m2)

80 (34.9)

101 (35.4)

58 (33.0)

Obese (≥30 kg/m2)

66 (28.8)

73 (25.6)

53 (30.1)

2.4±1.0

2.5±0.9

2.5±1.0

No

124 (54.2)

208 (73.0)

149 (84.7)

Yes

105 (45.8)

77 (27.0)

27 (15.3)

43.1±7.9

42.8±7.1

43.2±7.6

>0.1

32.0±12.5

31.4±10.9

31.5±10.7

>0.1

38.7±5.5

37.7±5.2

37.5±4.8

0.08

19 (8.3)

18 (6.3)

9 (5.1)

High School to <College

87 (38.0)

94 (33.0)

48 (27.3)

College to <Post-grad Study

72 (31.4)

96 (33.7)

71 (40.3)

≥Post-grad Study or Degree

51 (22.3)

77 (27.0)

48 (27.3)

166 (72.5)

250 (87.7)

152 (86.4)

46 (20.1)

17 (6.0)

17 (9.6)

17 (7.4)

18 (6.3)

7 (4.0)

115 (54.5)

125 (47.2)

83 (50.6)

73 (34.6)

98 (37.0)

56 (34.2)

P-value

Age in years
≤59
60-69
≥70

>0.1

Body Mass Index (kg/m2)

aMT6s(ng/mg creatinine)

>0.1

>0.1

Insomnia Rating

Body Fat Percentage
Whole Body Fat Mass (kg)
Whole Body Lean Mass (kg)

<0.001

Education
Less than High School

>0.1

Ethnicity
White (Non-Hispanic)
Black or African-American (NonHispanic)
Other

<0.001

Income Status
<$35,000
$35,000-<$75,0000
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>0.1

≥ $75,000

23 (10.9)

42 (15.8)

25 (15.2)

125 (65.8)

156 (67.2)

106 (10.7)

65 (34.2)

76 (32.8)

4 (29.3)

10 (4.4)

8 (2.8)

8 (4.6)

83 (36.2)

76 (26.7)

53 (30.1)

136 (59.4)

201 (70.5)

115 (65.3)

Tertile 1 (168.1-1158.5)

89 (38.9)

94 (33.0)

47 (26.7)

Tertile 2 (1159.4-1618.9)

65 (28.4)

103 (36.1)

62 (35.2)

Tertile 3 (1621.0-6497.7)

75 (32.7)

88 (30.9)

67 (38.1)

Tertile 1 (27.3-65.8)

100 (43.7)

75 (26.3)

55 (31.3)

Tertile 2 (65.9-74.7)

67 (29.3)

101 (35.4)

62 (35.2)

Tertile 3 (74.7-90.4)

62 (27.1)

109 (38.3)

59 (33.5)

212 (92.6)

271 (95.1)

167 (94.9)

17 (7.4)

14 (4.9)

9 (5.1)

228 (99.6)

283 (99.3)

175 (99.4)

1 (0.4)

2 (0.7)

1 (0.6)

221 (96.5)

277 (97.2)

174 (98.9)

8 (3.5)

8 (2.8)

2 (1.1)

Never

124 (54.2)

147 (51.6)

94 (53.4)

Former

85 (37.1)

124 (43.5)

68 (38.6)

Current

20 (8.7)

14 (4.9)

14 (8.0)

Employment Status
Not employed
Employed

>0.1

Marital Status
Never Married
Widowed/Divorced/Separated
Married/Marriage-like
relationship

0.05

Total Caloric Intake (kcal/day)

0.07

Modified Healthy Eating Index

<0.001

Prior Diagnosis of Diabetes
No
Yes

>0.1

Diagnosis of Stroke
No
Yes

>0.1

Diagnosis of MI
No
Yes

>0.1

Cigarette smoking
>0.1

Alcohol consumption

>0.1
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Non drinker

39 (17.0)

43 (15.1)

27 (15.3)

Former drinker

52 (22.7)

51 (17.9)

38 (21.6)

<1 drink per month

35 (15.3)

37 (13.0)

20 (11.4)

<1 drink per week

43 (18.8)

51 (17.9)

37 (21.0)

1 to <7 drinks per week

45 (19.6)

73 (25.6)

33 (18.8)

15 (6.6)

30 (10.5)

21 (11.9)

174.9±146.9

162.8±123.9

173.1±137.6

>0.1

13.3±16.5

12.4±12.2

11.8±13.1

>0.1

6.6±2.7

6.4±2.5

6.2±2.3

>0.1

78.2±22.2

83.2±16.6

81.0±19.7

>0.1

No (<0.06)

188 (82.1)

261 (91.6)

161 (91.5)

Yes (≥0.06)

41 (17.9)

24 (8.4)

15 (8.5)

77.9±35.1

89.1±24.8

84.1±30.2

Current Drinkers

7+ drinks per week
Caffeine Consumption (mg)
Energy
expenditure
from
physical activity (METS hr/wk)
Social Strain
Physical Functioning
Depressive Symptoms

Limitations
problems
a

<0.001
due

to

emotional

METS (metabolic equivalent task scores)
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0.09

Table 4. Multivariable linear regression describing influence of baseline sleep duration on body
mass index (kg/m2), N=690
Sleep duration, ≤6 hours^
Sleep duration, ≥8 hours^
Unadjusted
Model 1

β (95% CI)
0.06 (-0.08, 0.20)
0.06 (-0.08, 0.20)

β (95% CI)
0.06 (-0.09, 0.20)
0.06 (-0.09, 0.20)

P Value
0.609
0.617

Model 2

0.03 (-0.11, 0.17)

0.07 (-0.08, 0.22)

0.683

Model 3

-0.02 (-0.15, 0.12)

0.06 (-0.08, 0.21)

0.576

Model 4

0.03 (-0.11, 0.17)

0.05 (-0.10, 0.20)

0.793

Model 5

0.01 (-0.13, 0.14)

0.03 (-0.11, 0.17)

0.905

Model 6

0.03 (-0.11, 0.16)

0.05 (-0.09, 0.20)

0.783

Model 7

0.04 (-0.09, 0.18)

0.06 (-0.08, 0.21)

0.671

Model 8

-0.04 (-0.18, 0.09)

0.02 (-0.12, 0.16)

0.680

Model 9

-0.05 (-0.18, 0.09)

0.02 (-0.12, 0.16)

0.677

^ Reference category: 7 hours
Model 1 adjusted for age
Model 2 adjusted for age, insomnia, and aMT6s
Model 3 adjusted for age, education, ethnicity, and marital status
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional
limitations constructs
Model 6 adjusted for age, smoking status, alcohol consumption
Model 7 adjusted for age, diabetes, and stroke
Model 8 adjusted for age, all variables from weight models 3-7
Model 9 adjusted for age, all variables from weight models 2-7
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Table 5. Multivariable linear regression describing influence of baseline sleep duration on body
fat percentage, N=684
Sleep duration, ≤6 hours^
Sleep duration, ≥8 hours^
Unadjusted
Model 1

β (95% CI)
-0.44 (-1.73, 0.84)
-0.45 (-1.73, 0.84)

β (95% CI)
0.21 (-1.18, 1.61)
0.21 (-1.19, 1.60)

P Value
0.650
0.648

Model 2

-0.73 (-2.03, 0.57)

0.26 (-1.13, 1.65)

0.376

Model 3

-0.91 (-2.20, 0.37)

0.29 (-1.08, 1.65)

0.214

Model 4

-0.76 (-2.00, 0.49)

0.04 (-1.30, 1.37)

0.412

Model 5

-0.83 (2.06, 0.40)

0.08 (-1.23, 1.40)

0.318

Model 6

-0.66 (-1.92, 0.61)

0.17 (-1.20, 1.54)

0.456

Model 7

-0.50 (-1.79, 0.78)

0.19 (-1.20, 1.58)

0.607

Model 8

-0.99 (-2.21, 0.23)

0.09 (-1.18, 1.37)

0.190

Model 9

-1.09 (-2.32, 0.13)

0.13 (-1.15, 1.40)

0.140

^Reference category: 7 hours
Model 1 adjusted for age
Model 2 adjusted for age, insomnia, and aMT6s
Model 3 adjusted for age, education, ethnicity, and marital status
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional
limitations constructs
Model 6 adjusted for age, smoking status, alcohol consumption
Model 7 adjusted for age, diabetes, and stroke
Model 8 adjusted for age, all variables from weight models 3-7
Model 9 adjusted for age, all variables from weight models 2-7
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Table 6. Multivariable linear regression describing influence of baseline sleep duration on body
weight at year 6, N=547
Sleep duration, ≤6 hours^
Sleep duration, ≥8 hours^
Unadjusted
Model 1

β (95% CI)
2.22 (-1.16, 5.60)
2.04 (-1.28, 5.36)

β (95% CI)
1.51 (-2.14, 5.17)
1.50 (-2.09, 5.09)

P Value
0.413
0.452

Model 2

0.51 (-1.38, 2.40)

-0.64 (-2.68, 1.40)

0.574

Model 3

0.44 (-1.48, 2.36)

-0.59 (-2.64, 1.46)

0.656

Model 4

0.40 (-1.51, 2.32)

-0.70 (-2.74, 1.34)

0.602

Model 5

0.56 (-1.36, 2.48)

-0.58 (-2.64, 1.48)

0.588

Model 6

0.41 (-1.51, 2.33)

-0.69 (-2.74, 1.36)

0.604

Model 7

0.49 (-1.40, 2.39)

-0.66 (-2.71, 1.40)

0.575

Model 8

0.54 (-1.36, 2.54)

-0.64 (-2.69, 1.40)

0.559

Model 9

0.54 (-1.44, 2.53)

-0.71 (-2.80, 1.37)

0.539

Model 10

0.56 (-1.44, 2.56)

-0.71 (-2.80, 1.37)

0.539

^Reference category: 7 hours

Model 1 adjusted for age
Model 2 adjusted for age and baseline weight/percentage body fat
Model 3 adjusted for age, baseline weight/percentage body fat, insomnia, and aMT6s
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly
energy expenditure
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning
and emotional limitations constructs
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol
consumption Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8
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Table 7. Multivariable linear regression describing influence of baseline sleep duration on body
fat percentage at year 6, N=529
Sleep duration, ≤6 hours^
Sleep duration, ≥8 hours^
Unadjusted
Model 1

β (95% CI)
-0.24 (-1.77, 1.29)
-0.28 (-1.80, 1.25)

β (95% CI)
0.69 (-0.96, 2.34)
0.68 (-0.98, 2.32)

P Value
0.559
0.545

Model 2

-0.07 (-0.86, 0.71)

-0.45 (-1.30, 0.40)

0.568

Model 3

-0.13 (-0.93, 0.66)

-0.42 (-1.27, 0.44)

0.631

Model 4

-0.01 (-0.82, 0.79)

-0.38 (-1.23, 0.48)

0.653

Model 5

-0.03 (-0.83, 0.77)

-0.39 (-1.34, 0.46)

0.631

Model 6

-0.14 (-0.94, 0.66)

-0.50 (-1.35, 0.36)

0.517

Model 7

-0.11 (-0.91, 0.68)

-0.45 (-1.32, 0.41)

0.577

Model 8

-0.06 (-0.85, 0.73)

-0.45 (-1.30, 0.40)

0.560

Model 9

-0.08 (-0.91, 0.75)

-0.39 (-1.26, 0.48)

0.669

Model 10

-0.11 (-0.95, 0.73)

-0.38 (-1.26, 0.49)

0.685

^Reference category: 7 hours

Model 1 adjusted for age
Model 2 adjusted for age and baseline weight/percentage body fat
Model 3 adjusted for age, baseline weight/percentage body fat, insomnia, and aMT6s
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly
energy expenditure
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning
and emotional limitations constructs
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol
consumption Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8
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Table 8. Sleep insomnia status by study population characteristics in the Women’s
Health Initiative, n=690
Characteristic

No Insomnia
N=481

Insomnia
N=209

n (%) /Mean±SD

n (%) /Mean±SD

≤59

150 (31.2)

71 (34.0)

60-69

239 (49.7)

94 (45.0)

92 (19.1)

44 (21.0)

Normal Weight (<25 kg/m2)

186 (38.7)

73 (34.9)

Overweight (25 to <30 kg/m2)

162 (33.7)

77 (36.8)

Obese (≥30 kg/m2)

133 (27.6)

59 (28.3)

2.4±1.0

2.5±0.9

6 hours or less

124 (25.8)

105 (50.2)

7 hours

208 (43.2)

77 (36.8)

8 hours or more

149 (31.0)

27 (12.9)

30.6±3.8

31.0±3.9

>0.1

31.3±11.1

32.4±12.0

>0.1

37.8±5.2

38.3±5.3

>0.1

31 (6.4)

15 (7.2)

High School to <College

148 (30.8)

81 (38.7)

College to <Post-grad Study

178 (37.0)

61 (29.2)

≥Post-grad Study or Degree

124 (25.8)

52 (24.9)

396 (82.3)

172 (82.3)

50 (10.4)

30 (14.3)

35 (7.3)

7 (3.4)

P-value

Age in years

≥70

>0.1

Body Mass Index (kg/m2)

aMT6s (ng/mg creatinine)

>0.1

>0.1

Sleep Duration

Body Fat Percentage
Whole Body Fat Mass (g)
Whole Body Lean Mass (g)

<0.001

Education
Less than High School

>0.1

Ethnicity
White (Non-Hispanic)
Black or African-American
(Non-Hispanic)
Other
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0.06

Income Status
<$35,000

218 (49.0)

105 (53.8)

$35,000-<$75,0000

160 (36.0)

67 (34.4)

67 (15.1)

23 (11.8)

Not employed

264 (66.2)

123 (71.1)

Employed

135 (33.8)

50 (28.9)

22 (4.6)

4 (1.9)

Widowed/Divorced/Separated

136 (28.3)

76 (36.4)

Married/Marriage-like
relationship

323 (67.1)

129 (61.7)

Tertile 1 (168.1-1158.5)

163 (33.8)

67 (32.1)

Tertile 2 (1159.4-1618.9)

159 (33.1)

74 (35.4)

Tertile 3 (1621.0-6497.7)

159 (33.1)

68 (32.5)

Tertile 1 (27.3-65.8)

151 (31.4)

79 (37.8)

Tertile 2 (65.9-74.7)

160 (33.3)

69 (33.0)

Tertile 3 (74.7-90.4)

170 (35.3)

61 (29.2)

452 (94.0)

198 (94.7)

29 (6.0)

11 (5.3)

478 (99.4)

208 (99.2)

3 (0.6)

1 (0.5)

468 (97.3)

204 (97.6)

13 (2.7)

5 (2.4)

266 (55.3)

99 (47.4)

≥ $75,000

>0.1

Employment Status
>0.1

Marital Status
Never Married

<0.05

Total Caloric Intake (kcal/day)

>0.1

Modified Healthy Eating Index

>0.1

Diagnosis of Diabetes
No
Yes

>0.1

Diagnosis of Stroke
No
Yes

>0.1

Diagnosis of MI
No
Yes

>0.1

Cigarette smoking
>0.1
Never
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Former

180 (37.4)

97 (46.4)

Current

35 (7.3)

13 (6.2)

Non drinker

77 (16.0)

32 (15.3)

Past drinker

94 (19.6)

47 (22.5)

<1 drink per month

65 (13.5)

27 (12.9)

<1 drink per week

93 (19.3)

38 (18.2)

110 (22.9)

41 (19.6)

42 (8.7)

24 (11.5)

172.7±136.6

161.9±132.4

>0.1

12.3±13.5

13.1±15.1

>0.1

6.3±2.4

6.7±2.7

>0.1

83.5±17.3

75.2±22.8

No (<0.06)

452 (94.0)

158 (75.6)

Yes (≥0.06)

29 (6.0)

51 (22.4)

89.5±23.3

71.6±39.5

Alcohol consumption

Current Drinkers
>0.1

1 to <7 drinks per week
7+ drinks per week
Caffeine Consumption (mg)
Energy
expenditure
from
physical activity (METS hr/wk)
Social Strain
Physical Functioning

<0.001

Depressive Symptoms

Limitations due to emotional
problems
a

<0.001

METS (metabolic equivalent task scores)
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<0.001

Table 9. Multivariable linear regression describing influence of baseline insomnia status on baseline
body mass index and percent body fat^
Body Mass Index (kg/m2)
Body Fat Percentage
N=690
N=684
β (95% CI)
P Value
β (95% CI)
P Value
Unadjusted
0.04 (-0.09, 0.17)
0.517
0.45 (-0.75, 1.66)
0.458
Model 1

0.04 (-0.09, 0.17)

0.525

0.45 (-0.75, 1.65)

0.459

Model 2

0.05 (-0.08, 0.19)

0.441

0.71 (-0.52, 1.94)

0.257

Model 3

0.03 (-0.10, 0.16)

0.663

0.39 (-0.80, 1.58)

0.524

Model 4

0.04 (-0.09, 0.17)

0.525

0.43 (-0.72, 1.58)

0.466

Model 5

-0.05 (-0.18, 0.08)

0.482

-0.19 (-1.39,1.01)

0.759

Model 6

0.02 (-0.11, 0.15)

0.762

0.31 (-0.87, 1.50)

0.600

Model 7

0.05 (-0.08, 0.18)

0.474

0.48 (-0.72, 1.68)

0.431

Model 8

-0.04 (-0.17, 0.09)

0.535

0.04 (-0.13, 1.21)

0.949

Model 9

-0.02 (-0.15, 0.11)

0.736

0.32 (-0.88, 1.52)

0.603

^Reference category: no insomnia
Model 1 adjusted for age
Model 2 adjusted for age, sleep duration, and aMT6s
Model 3 adjusted for age, education, ethnicity, and marital status
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional limitations
constructs
Model 6 adjusted for age, smoking status, alcohol consumption
Model 7 adjusted for age, diabetes, and stroke
Model 8 adjusted for age, all variables from weight models 3-7
Model 9 adjusted for age, all variables from weight models 2-7
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Table 10. Multivariable linear regression describing influence of baseline insomnia status on
body weight and body fat percent at year 6
Body Weight (kg)^
Body Fat Percentage (%)^
N=547
N=529
β (95% CI)
P Value
β (95% CI)
P Value
Unadjusted 2.33 (-0.85, 5.52)
0.151
1.12 (-0.32, 2.56)
0.128
Model 1
2.12 (-1.01, 5.25)
0.185
1.06 (-0.38, 2.49)
0.149
Model 2
0.75 (-1.03, 2.53)
0.410
0.58 (-0.16, 1.32)
0.124
Model 3

0.55 (-1.29, 2.38)

0.558

0.52 (-0.24, 1.28)

0.176

Model 4

0.51 (-1.29, 2.31)

0.576

0.46 (-0.29, 1.21)

0.225

Model 5

0.80 (-0.99, 2.59)

0.379

0.56 (-0.18, 1.30)

0.136

Model 6

0.53 (-1.36, 2.43)

0.579

0.58 (-0.22, 1.37)

0.154

Model 7

0.50 (-1.29, 2.29)

0.583

0.58, (-0.17, 1.33)

0.128

Model 8

0.75 (-1.03, 2.54)

0.406

0.59 (-0.15, 1.33)

0.118

Model 9

0.25 (-1.69, 2.19)

0.799

0.40 (-0.42, 1.21)

0.339

Model 10

0.02 (-1.96, 2.00)

0.983

0.34 (-0.49, 1.17)

0.424

^Reference category: no insomnia
Model 1 adjusted for age
Model 2 adjusted for age and baseline weight/percentage body fat
Model 3 adjusted for age, baseline weight/percentage body fat, sleep duration, and aMT6s
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly energy
expenditure
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning
and emotional limitations constructs
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol consumption
Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8
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Table 11. Urinary Levels of Melatonin Metabolite by study population characteristics in
the Women’s Health Initiative, N=690
aMT6s (ng/mg creatinine)
Characteristic

P-Value
Geometric Mean 95%CI

Age (years)
≤59

12.8 (11.2, 14.6)

60-69

11.8 (10.6, 13.0)

≥70

0.01

9.8 (8.4, 11.5)

Body Mass Index (kg/m2)
Normal Weight (<25 kg/m2)

14.2 (12.7, 15.8)

Overweight (25 to <30 kg/m2)

10.9 (9.7, 12.3)

Obese (≥30 kg/m2)

<0.001

9.7 (8.4, 11.2)

Sleep Duration
6 hours or less

10.7 (9.4, 12.2)

7 hours

12.3 (11.1, 13.6)

8 hours or more

11.9 (10.2, 13.9)

>0.1

Insomnia
No (<9)

11.5 (10.6, 12.6)

Yes (≥9)

12.0 (10.6, 13.6)

>0.1

Education
Less than High School

7.8 (5.9, 10.4)

High School to <College

11.5 (10.2, 13.0)

College to <Post-grad Study

11.8 (10.5, 13.4)

≥Post-grad Study or Degree

13.0 (11.3, 14.8)

0.01

Ethnicity
White (Non-Hispanic)

12.3 (11.4, 13.3)

Black or African-American (Non-Hispanic)

8.1 (6.4, 10.3)

Other

0.001

11.4 (8.7, 15.0)

Income Status
<$35,000

11.4 (10.3, 12.6)

$35,000 - $75,0000

12.3 (10.8, 14.0)
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>0.1

≥ $75,000

11.6 (9.4, 14.3)

Employment Status
Not employed

11.4 (10.4, 12.5)

Employed

11.7 (10.1, 13.5)

>0.1

Marital Status
Never Married

12.1 (8.4, 17.3)

Widowed/Divorced/Separated

10.4 (9.1, 11.8)

Married/Marriage-like relationship

12.3 (11.3, 13.4)

>0.1

Total Caloric Intake (kcal/day)
Tertile 1 (168.1-1158.5)

11.1 (9.8, 12.6)

Tertile 2 (1159.4-161 8.9)

11.6 (10.2, 13.1)

Tertile 3 (1621.0-6497.7)

12.4 (10.9, 14.0)

>0.1

Modified Healthy Eating Index
Tertile 1 (27.3-65.8)

10.7 (9.4, 12.2)

Tertile 2 (65.9-74.7)

11.8 (10.4, 13.4)

Tertile 3 (74.7-90.4)

12.6 (11.2, 14.1)

>0.1

Prior Diagnosis of Diabetes
No

12.1 (11.3, 17.8)

Yes

6.4 (4.3, 9.5)

<0.001

History of Stroke
No

11.7 (10.9, 12.6)

Yes

3.8 (0.6, 22.7)

0.02

History of MI
No

11.8 (10.9, 12.6)

Yes

8.6 (4.8, 15.1)

>0.1

Cigarette smoking
Never

11.6 (10.6, 12.7)

Former

11.8 (10.5, 13.2)

Current

11.4 (8.1, 16.2)

>0.1

Alcohol consumption
Non drinker

11.4 (9.4, 13.6)
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0.06

Former drinker

9.5 (8.0, 11.3)

Current drinker
<1 drink per month

13.6 (11.6, 16.0)

<1 drink per week

12.7 (10.9, 14.9)

1 to <7 drinks per week

12.1 (10.4, 14.2)

7+ drinks per week

11.8 (9.4, 14.7)

Depressive Symptoms
No (<0.06)

11.6 (10.7, 12.5)

Yes (≥0.06)

12.5 (10.0, 15.7)

> 0.1

Correlation with aMT6s

P-Value

Body Fat Percentage

-0.147

<0.001

Whole Body Fat Mass (kg)

-0.173

<0.001

Whole Body Lean Mass (kg)

-0.165

<0.001

Caffeine Consumption (mg)

0.054

>0.1

Energy expenditure from physical activity
(METSa hr/wk)

0.055

Social Strain
Physical Functioning
Limitations due to emotional problems
a

METS (metabolic equivalent task scores)

40

>0.1

-0.018

>0.1

0.114

<0.001

-0.009

>0.1

Table 12. Multivariable linear regression describing influence of baseline creatinine-adjusted
melatonin metabolite (ng/mg of creatinine) on baseline body mass index and body fat percentage
Body Mass Index (kg/m2)
Body Fat Percentage
N=690
N=684
β (95% CI)
P Value
β (95% CI)
P Value
Unadjusted
-0.14 (-0.20, -0.07)
<0.001
-1.03 (-1.61, -0.45)
0.001
Model 1

-0.14 (-0.20, -0.08)

<0.001

-1.04 (-1.62, -0.46)

<0.001

Model 2

-0.14 (-0.20, -0.08)

<0.001

-1.07 (-1.65, -0.49)

<0.001

Model 3

-0.11 (-0.17, -0.05)

0.001

-0.84 (-1.42, -0.26)

0.005

Model 4

-0.13 (-0.19, -0.06)

<0.001

-0.84 (-1.40, -0.28)

0.004

Model 5

-0.10 (-0.16, -0.05)

0.001

-0.73 (-1.28, -0.17)

0.010

Model 6

-0.13 (-0.19, -0.07)

<0.001

-0.98 (-1.55, -0.40)

0.001

Model 7

-0.12 (-0.19, -0.06)

<0.001

-0.95 (-1.54, -0.36)

0.002

Model 8

-0.09 (-0.15, -0.03)

0.004

-0.61 (-1.16, -0.06)

0.029

Model 9

-0.09 (-0.15, -0.03)

0.004

-0.63 (-1.18, -0.08)

0.024

Model 1 adjusted for age
Model 2 adjusted for age, insomnia, and sleep duration,
Model 3 adjusted for age, education, ethnicity, and marital status
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional limitations
constructs
Model 6 adjusted for age, smoking status, alcohol consumption
Model 7 adjusted for age, diabetes, and stroke
Model 8 adjusted for age, all variables from weight models 3-7
Model 9 adjusted for age, all variables from weight models 2-7
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Table 13. Multivariable linear regression describing influence of baseline creatinine-adjusted
melatonin metabolite (ng/mg of creatinine) on body weight and body fat percentage at year 6
Body Weight (kg)
Body Fat Percentage (%)
N=543
N=525
β (95% CI)
P Value
β (95% CI)
P Value
Unadjusted
-1.53 (-3.15, 0.08)
0.062
-0.34 (-1.07, 0.38)
0.354
Model 1
-1.79 (-3.38, -0.20)
0.027
-0.40 (-1.13, 0.32)
0.277
Model 2
Model 3

0.34 (-0.40, 1.09)
0.33 (-0.41, 1.08)

0.362
0.379

0.33 (-0.05, 0.70)
0.32 (-0.05, 0.70)

0.089
0.091

Model 4

0.36 (-0.39, 1.11)

0.344

0.31 (-0.07, 0.70)

0.109

Model 5

0.36 (-0.39, 1.10)

0.347

0.32 (-0.05, 0.70)

0.089

Model 6

0.35 (-0.40, 1.10)

0.355

0.33 (-0.05, 0.70)

0.089

Model 7

0.32 (-0.44, 1.07)

0.407

0.32 (-0.06, 0.71)

0.094

Model 8

0.38 (-0.37, 1.13)

0.320

0.34 (-0.04, 0.72)

0.079

Model 9

0.41 (-0.36, 1.17)

0.299

0.33 (-0.06, 0.72)

0.101

Model 10

0.40 (-0.37, 1.17)

0.305

0.33 (-0.06, 0.72)

0.098

Model 1 adjusted for age
Model 2 adjusted for age and baseline weight/percentage body fat
Model 3 adjusted for age, baseline weight/percentage body fat, insomnia, and sleep duration
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly energy
expenditure
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning
and emotional limitations constructs
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol consumption
Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8
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Figure 1: Mixed model regression describing influence of baseline aMT6s on body fat
percentage at baseline, year 3, and year 6

Triennial variations in body fat percentage by baseline melatonin
metabolite (age-adjusted)
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Figure 2: Mixed model regression describing influence of baseline aMT6s on weight at
baseline, year 3, and year 6
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